Browse our anti-Advanced Glycosylation End Product-Specific Receptor (AGER) Antibodies

Full name:
anti-Advanced Glycosylation End Product-Specific Receptor Antibodies (AGER)
On www.antibodies-online.com are 289 Advanced Glycosylation End Product-Specific Receptor (AGER) Antibodies from 31 different suppliers available. Additionally we are shipping Advanced Glycosylation End Product-Specific Receptor Kits (80) and Advanced Glycosylation End Product-Specific Receptor Proteins (38) and many more products for this protein. A total of 424 Advanced Glycosylation End Product-Specific Receptor products are currently listed.
Synonyms:
AGER, RAGE
list all antibodies Gene Name GeneID UniProt
AGER 177 Q15109
AGER 11596  
AGER 81722  

Show all species

Show all synonyms

Most Popular Reactivities for anti-Advanced Glycosylation End Product-Specific Receptor (AGER) Antibodies

Select your species and application

anti-Human Antibodies:

anti-Mouse (Murine) Antibodies:

anti-Rat (Rattus) Antibodies:

All available anti-Advanced Glycosylation End Product-Specific Receptor Antibodies

Go to our pre-filtered search.

Top referenced anti-Advanced Glycosylation End Product-Specific Receptor Antibodies

  1. Human Polyclonal AGER Primary Antibody for IHC (p), WB - ABIN389027 : Schlueter, Hauke, Flohr, Rogalla, Bullerdiek: Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? in Biochimica et biophysica acta 2003 (PubMed)
    Show all 4 references for 389027

  2. Human Polyclonal AGER Primary Antibody for IF, IHC (p) - ABIN1108826 : Bierhaus, Haslbeck, Humpert, Liliensiek, Dehmer, Morcos, Sayed, Andrassy, Schiekofer, Schneider, Schulz, Heuss, Neundörfer, Dierl, Huber, Tritschler, Schmidt, Schwaninger, Haering, Schleicher, Kasper et al.: Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. ... in The Journal of clinical investigation 2004 (PubMed)
    Show all 4 references for 1108826

  3. Human Polyclonal AGER Primary Antibody for EIA, IHC (p) - ABIN357685 : Shanmugam, Kim, Lanting, Natarajan: Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. in The Journal of biological chemistry 2003 (PubMed)
    Show all 3 references for 357685

  4. Cow (Bovine) Polyclonal AGER Primary Antibody for WB - ABIN2786877 : Luo, Saiardi, Nagata, Ye, Yu, Jung, Luo, Jain, Sawa, Snyder: GRAB: a physiologic guanine nucleotide exchange factor for Rab3A, which interacts with inositol hexakisphosphate kinase. in Neuron 2001 (PubMed)
    Show all 2 references for 2786877

  5. Human Polyclonal AGER Primary Antibody for EIA, IHC (p) - ABIN359696 : Miyata, Akashi, Nishida: Molecular cloning and characterization of a novel member of the MAP kinase superfamily. in Genes to cells : devoted to molecular & cellular mechanisms 1999 (PubMed)
    Show all 2 references for 359696

  6. Cow (Bovine) Polyclonal AGER Primary Antibody for WB - ABIN2776831 : Galichet, Weibel, Heizmann: Calcium-regulated intramembrane proteolysis of the RAGE receptor. in Biochemical and biophysical research communications 2008 (PubMed)

  7. Human Polyclonal AGER Primary Antibody for IF, WB - ABIN390897 : Peng, Lu, Wang, Yan, Chen, Zhang, Zhang, Shen: RAGE gene polymorphisms are associated with circulating levels of endogenous secretory RAGE but not with coronary artery disease in Chinese patients with type 2 diabetes mellitus. in Archives of medical research 2009 (PubMed)

  8. Human Polyclonal AGER Primary Antibody for FACS, IHC (p) - ABIN651054 : Rojas, Figueroa, Morales: Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. in Carcinogenesis 2010 (PubMed)

  9. Human Polyclonal AGER Primary Antibody for IHC, WB - ABIN2776917 : Lieuw-a-Fa, Schalkwijk, Engelse, van Hinsbergh: Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. in Thrombosis and haemostasis 2006 (PubMed)

More Antibodies against Advanced Glycosylation End Product-Specific Receptor Interaction Partners

Human Advanced Glycosylation End Product-Specific Receptor (AGER) interaction partners

  1. The severity of acute respiratory distress syndrome in preterm infants seemed to be associated with the plasma level of sRAGE and AQP5 (show AQP5 Antibodies): the more severe the disease, the higher the plasma level of sRAGE and AQP5 (show AQP5 Antibodies)

  2. Advanced glycation end products are capable of inducing VEGF (show VEGFA Antibodies) production and inflammatory responses via RAGE-NF-kappaB (show NFKB1 Antibodies) pathway activation in synoviocytes.

  3. Atrial tissue expression of RAGE was significantly associated with atrial fibrosis in patients with mitral valve disease.

  4. RAGE drives tumor progression and metastasis through distinct tumor cell-intrinsic and -extrinsic mechanisms, and may represent a novel and therapeutically viable approach for treating metastatic cancers.

  5. these studies suggest that expression of RAGE in T cells of patients at risk for type 1 diabetes progressing to disease predates dysglycemia

  6. These studies confirm that intranasal insulin (show INS Antibodies) improves indexes of experimental DPN but indicates that females with DPN may differ in their underlying phenotype. RN mice had partial but incomplete protection from underlying DPN and lesser impacts from insulin (show INS Antibodies).

  7. findings show that RAGE binds RNA molecules in a sequence-independent manner and enhances cellular RNA uptake into endosomes; gain- and loss-of-function studies demonstrate that RAGE increases the sensitivity of all ssRNA-sensing TLRs (TLR7 (show TLR7 Antibodies), TLR8 (show TLR8 Antibodies), TLR13 (show Tlr13 Antibodies)), suggesting RAGE is an integral part of the endosomal nucleic acid-sensing system

  8. HMGB1 (show HMGB1 Antibodies) and sRAGE are not affected by combined antiretroviral therapy for HIV infection

  9. The binding interface between S100A12 (show S100A12 Antibodies) and the V domain of RAGE has been identified and mapped.

  10. Gly82Ser and 2184 A/G RAGE polymorphisms were related to the mortality due to the breast cancer and -419 A/C glyoxalase I (show GLO1 Antibodies) polymorphism was related to the overall mortality of the patients suggesting their role not only in the risk of breast cancer but also in the outcome of patients with breast cancer.

Cow (Bovine) Advanced Glycosylation End Product-Specific Receptor (AGER) interaction partners

  1. Our results suggested that the increased RAGE expression in inflammatory circumstances and interaction with AGEs are risk factors in decreasing of aggrecan (show ACAN Antibodies) content in nucleus pulposus.

Mouse (Murine) Advanced Glycosylation End Product-Specific Receptor (AGER) interaction partners

  1. Ager deletion enhances ischemic muscle inflammation, angiogenesis, and blood flow recovery in diabetic mice.

  2. HMGB1 (show HMGB1 Antibodies) neither exerts influence on cardiac remodeling by binding to RAGE nor induces apoptosis of cardiomyocytes under physiological condition

  3. Our results indicate that lack of RAGE has no significant impact on septic arthritis. However, RAGE-/- mice had significantly higher BMD (show BEST1 Antibodies) compared to WT mice, which coincided with lower IL-17A (show IL17A Antibodies) in RAGE-/- mice. In sepsis, RAGE deficiency impairs bacterial kidney clearance.

  4. SAA (show SAA1 Antibodies) is a potential new uremic toxin involved in uremia-related atherosclerosis through interaction with RAGE.

  5. that selective RAGE regulation reflects a self-protective mechanism to maintain low levels of RAGE ligands

  6. Data show that receptor for advanced glycation end products (RAGE) impairs collateral growth in a diabetic setting and also in a non-diabetic setting, indicting the importance of RAGE and alternate RAGE ligands in the setting of collateral vessel growth.

  7. These findings demonstrate the role for RAGE-dependent IL-10 (show IL10 Antibodies) suppression as a key modulator of mortality from Gram-negative sepsis.

  8. HMGB1 (show HMGB1 Antibodies) promotes intraoral palatal wound healing through RAGE-dependent mechanisms.

  9. These findings suggest that the inhibitory effect of these plant extracts on the activation of AGEs/RAGE/SphK1 (show SPHK1 Antibodies) signaling pathway in db/db (show LEPR Antibodies) diabetic mice kidney is a novel mechanism by which they exert renoprotective effects in diabetic nephropathy.

  10. Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 (show DIAPH1 Antibodies) Signal Transduction.

Advanced Glycosylation End Product-Specific Receptor (AGER) Antigen Profile

Antigen Summary

The advanced glycosylation end product (AGE) receptor encoded by this gene is a member of the immunoglobulin superfamily of cell surface receptors. It is a multiligand receptor, and besides AGE, interacts with other molecules implicated in homeostasis, development, and inflammation, and certain diseases, such as diabetes and Alzheimer's disease. Many alternatively spliced transcript variants encoding different isoforms, as well as non-protein-coding variants, have been described for this gene (PMID:18089847).

Alternative names and synonyms associated with Advanced Glycosylation End Product-Specific Receptor (AGER)

  • advanced glycosylation end product-specific receptor (AGER) antibody
  • advanced glycosylation end product-specific receptor (Ager) antibody
  • advanced glycosylation end product-specific receptor (LOC100343142) antibody
  • AGER antibody
  • RAGE antibody

Protein level used designations for AGER

advanced glycosylation end product-specific receptor , RAGE isoform NtRAGE-delta , RAGE isoform sRAGE-delta , RAGE/AGER , advanced glycation end product receptor , advanced glycosylation end product-specific receptor variant 1 , advanced glycosylation end product-specific receptor variant 3 , advanced glycosylation end product-specific receptor variant 4 , advanced glycosylation end product-specific receptor variant 5 , advanced glycosylation end product-specific receptor variant 6 , advanced glycosylation end product-specific receptor variant 7 , advanced glycosylation end product-specific receptor variant 8 , receptor for advanced glycosylation end products , advanced glycation end-products receptor , advanced glycosylation end product-specific receptor variant 2

GENE ID SPECIES
462584 Pan troglodytes
177 Homo sapiens
403168 Canis lupus familiaris
396591 Sus scrofa
280986 Bos taurus
11596 Mus musculus
81722 Rattus norvegicus
100343142 Oryctolagus cuniculus
100726130 Cavia porcellus
101111586 Ovis aries
Selected quality suppliers for anti-Advanced Glycosylation End Product-Specific Receptor (AGER) Antibodies
Did you look for something else?